

# Christine Goffinet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4291239/publications.pdf>

Version: 2024-02-01

46  
papers

4,691  
citations

279487

23  
h-index

243296

44  
g-index

68  
all docs

68  
docs citations

68  
times ranked

9710  
citing authors

#	ARTICLE	IF	CITATIONS
1	Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single-cell transcriptomics. <i>Molecular Therapy</i> , 2022, 30, 1952-1965.	3.7	20
2	Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy. <i>MBio</i> , 2022, 13, e0036422.	1.8	17
3	Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies. <i>Journal of Clinical Immunology</i> , 2022, 42, 1111-1129.	2.0	17
4	Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. <i>Nature Biotechnology</i> , 2021, 39, 705-716.	9.4	129
5	Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics. <i>Lancet Microbe</i> , The, 2021, 2, e210-e218.	3.4	71
6	The barrier functions of crude cervical mucus plugs against HIV-1 infection in the context of cell-free and cell-to-cell transmission. <i>Aids</i> , 2021, 35, 2105-2117.	1.0	4
7	Human IFITM3 restricts chikungunya virus and Mayaro virus infection and is susceptible to virus-mediated counteraction. <i>Life Science Alliance</i> , 2021, 4, e202000909.	1.3	10
8	IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro. <i>Nature Communications</i> , 2021, 12, 4584.	5.8	129
9	Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	70
10	A realistic transfer method reveals low risk of SARS-CoV-2 transmission via contaminated euro coins and banknotes. <i>IScience</i> , 2021, 24, 102908.	1.9	21
11	Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19. <i>Nature Communications</i> , 2021, 12, 4869.	5.8	68
12	Single-cell analysis of arthritogenic alphavirus-infected human synovial fibroblasts links low abundance of viral RNA to induction of innate immunity and arthralgia-associated gene expression. <i>Emerging Microbes and Infections</i> , 2021, 10, 2151-2168.	3.0	11
13	SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. <i>Cell</i> , 2021, 184, 6243-6261.e27.	13.5	277
14	Labyrinthopeptins Exert Broad-Spectrum Antiviral Activity through Lipid-Binding-Mediated Virolysis. <i>Journal of Virology</i> , 2020, 94, .	1.5	30
15	Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. <i>Cell</i> , 2020, 182, 1419-1440.e23.	13.5	1,162
16	Absence of cGAS-mediated type I IFN responses in HIV-1-infected T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 19475-19486.	3.3	20
17	COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. <i>Nature Biotechnology</i> , 2020, 38, 970-979.	9.4	887
18	Alert from a Distant Neighbor: Spread of Antiviral Immunity through Anion Channels. <i>Immunity</i> , 2020, 52, 719-721.	6.6	0

#	ARTICLE	IF	CITATIONS
19	Quantitative Proteomics of Uukuniemi Virus-host Cell Interactions Reveals GBF1 as Proviral Host Factor for Phleboviruses. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 2401-2417.	2.5	12
20	Characterization of Endogenous SERINC5 Protein as Anti-HIV-1 Factor. <i>Journal of Virology</i> , 2019, 93, .	1.5	17
21	SIVcol Nef counteracts SERINC5 by promoting its proteasomal degradation but does not efficiently enhance HIV-1 replication in human CD4+ T cells and lymphoid tissue. <i>PLoS Pathogens</i> , 2018, 14, e1007269.	2.1	25
22	The Antiviral Activity of the Cellular Glycoprotein LGALS3BP/90K Is Species Specific. <i>Journal of Virology</i> , 2018, 92, .	1.5	22
23	Susceptibility of Chikungunya Virus to Inactivation by Heat and Commercially and World Health Organization-Recommended Biocides. <i>Journal of Infectious Diseases</i> , 2018, 218, 1507-1510.	1.9	2
24	Potent and reversible lentiviral vector restriction in murine induced pluripotent stem cells. <i>Retrovirology</i> , 2017, 14, 34.	0.9	11
25	Cellular Antiviral Factors that Target Particle Infectivity of HIV-1. <i>Current HIV Research</i> , 2016, 14, 211-216.	0.2	11
26	cGAS-Mediated Innate Immunity Spreads Intercellularly through HIV-1 Env-Induced Membrane Fusion Sites. <i>Cell Host and Microbe</i> , 2016, 20, 443-457.	5.1	46
27	Inactivation of HCV and HIV by microwave: a novel approach for prevention of virus transmission among people who inject drugs. <i>Scientific Reports</i> , 2016, 6, 36619.	1.6	14
28	Interferon- $\alpha$ -inducible cholesterol-25 $\alpha$ -hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation. <i>Hepatology</i> , 2015, 62, 702-714.	3.6	78
29	Peptide nanofibrils boost retroviral gene transfer and provide a rapid means for concentrating viruses. <i>Nature Nanotechnology</i> , 2013, 8, 130-136.	15.6	125
30	90K, an interferon-stimulated gene product, reduces the infectivity of HIV-1. <i>Retrovirology</i> , 2013, 10, 111.	0.9	43
31	The Cellular Antiviral Restriction Factor Tetherin Does Not Inhibit Poxviral Replication. <i>Journal of Virology</i> , 2012, 86, 1893-1896.	1.5	1
32	Reacquisition of Nef-Mediated Tetherin Antagonism in a Single In Vivo Passage of HIV-1 through Its Original Chimpanzee Host. <i>Cell Host and Microbe</i> , 2012, 12, 373-380.	5.1	35
33	In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 13688-13693.	3.3	86
34	Antagonism of CD317 Restriction of Human Immunodeficiency Virus Type 1 (HIV-1) Particle Release and Depletion of CD317 Are Separable Activities of HIV-1 Vpu. <i>Journal of Virology</i> , 2010, 84, 4089-4094.	1.5	71
35	Endogenous CD317/Tetherin Limits Replication of HIV-1 and Murine Leukemia Virus in Rodent Cells and Is Resistant to Antagonists from Primate Viruses. <i>Journal of Virology</i> , 2010, 84, 11374-11384.	1.5	42
36	Pharmacovirological Impact of an Integrase Inhibitor on Human Immunodeficiency Virus Type 1 cDNA Species In Vivo. <i>Journal of Virology</i> , 2009, 83, 7706-7717.	1.5	14

#	ARTICLE	IF	CITATIONS
37	HIV-1 Antagonism of CD317 Is Species Specific and Involves Vpu-Mediated Proteasomal Degradation of the Restriction Factor. <i>Cell Host and Microbe</i> , 2009, 5, 285-297.	5.1	240
38	Human cyclin T1 expression ameliorates a T-cell-specific transcriptional limitation for HIV in transgenic rats, but is not sufficient for a spreading infection of prototypic R5 HIV-1 strains ex vivo. <i>Retrovirology</i> , 2009, 6, 2.	0.9	21
39	HIV-1 antagonism of CD317/tetherin is species-specific and involves Vpu-mediated proteasomal degradation of the intrinsic immunity factor. <i>Retrovirology</i> , 2009, 6, .	0.9	0
40	Aqueous extracts from peppermint, sage and lemon balm leaves display potent anti-HIV-1 activity by increasing the virion density. <i>Retrovirology</i> , 2008, 5, 27.	0.9	83
41	Mouse T-cells restrict replication of human immunodeficiency virus at the level of integration. <i>Retrovirology</i> , 2008, 5, 58.	0.9	24
42	HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 1015-1020.	3.3	48
43	Semen-Derived Amyloid Fibrils Drastically Enhance HIV Infection. <i>Cell</i> , 2007, 131, 1059-1071.	13.5	510
44	Primary T-cells from human CD4/CCR5-transgenic rats support all early steps of HIV-1 replication including integration, but display impaired viral gene expression. <i>Retrovirology</i> , 2007, 4, 53.	0.9	27
45	Efficient nonviral gene delivery into primary lymphocytes from rats and mice. <i>FASEB Journal</i> , 2006, 20, 500-502.	0.2	56
46	Human Lungs Show&nbsp;Limited Permissiveness for SARS-CoV-2 Due to Scarce ACE2 Levels But Strong Virus-Induced Immune Activation in Alveolar Macrophages. <i>SSRN Electronic Journal</i> , 0, , .	0.4	5